KI-7
Based on 1 Customer Validation
KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC50=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC50s of 2390 nM and 2550 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.16%
- CAS No.: 1489263-00-4
- Formula: C23H18N2O2
- Molecular Weight:354.40
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Covalent Screening Library
HY-L036
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Allosteric Modulators (AMs) Compound Library
HY-L170
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
All Adenosine Receptor Isoforms
More
Biological Activity
KI-7 (1 μM; 5-21 days; mesenchymal stem cells) induces a significant increase in mRNA expression of Runx2 and Osterix[1].
KI-7 (1 μM; 15-21 days) induced a significant increase in cell viability in both differentiation stages[1].
KI-7, as A2B adenosine receptor positive allosteric modulator in MSCs, demonstrating it is able to potentiate the effects of either adenosine and synthetic orthosteric A2B adenosine receptor agonists in mediating osteoblast differentiation in vitro. NECA, BAY 60-6583 and KI-7 induce a strong increase in IL-6 production. KI-7 is able to potentiate the effects of orthosteric agonists in both differentiation stages, even if the effect became significant only at 21 days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1489263-00-4
-
Appearance Solid
-
Molecular Weight 354.40
-
Formula C23H18N2O2
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC=C1)C(C2=CN(CC3=CC=CC=C3)C4=C2C=CC=C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 250 mg/mL (705.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Trincavelli ML, et al. Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta. 2014;1840(3):1194-1203. [Content Brief]
[2]. Trincavelli ML, et al. Osteoblast differentiation and survival: A role for A2B adenosine receptor allosteric modulators. Biochim Biophys Acta. 2014;1843(12):2957-2966. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL | 70.5418 mL |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL | 14.1084 mL | |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL | 7.0542 mL | |
| 15 mM | 0.1881 mL | 0.9406 mL | 1.8811 mL | 4.7028 mL | |
| 20 mM | 0.1411 mL | 0.7054 mL | 1.4108 mL | 3.5271 mL | |
| 25 mM | 0.1129 mL | 0.5643 mL | 1.1287 mL | 2.8217 mL | |
| 30 mM | 0.0941 mL | 0.4703 mL | 0.9406 mL | 2.3514 mL | |
| 40 mM | 0.0705 mL | 0.3527 mL | 0.7054 mL | 1.7635 mL | |
| 50 mM | 0.0564 mL | 0.2822 mL | 0.5643 mL | 1.4108 mL | |
| 60 mM | 0.0470 mL | 0.2351 mL | 0.4703 mL | 1.1757 mL | |
| 80 mM | 0.0353 mL | 0.1764 mL | 0.3527 mL | 0.8818 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.7054 mL |
KI-7 Related Classifications
HY-131032 Related Classifications
Powered by Bioz